Pioneering research by scientists at the Universities of Oxford and Birmingham published today [May 29th] in Nature has brought us a step closer to developing targeted therapies for inflammatory diseases.
The research team shows, for the first time, that different types of fibroblasts – the most common cells of connective tissue – are organised in different layers in the joint and are responsible for two very different forms of arthritis; osteoarthritis and rheumatoid arthritis.
Targeted therapies could alter the behaviour of fibroblasts to reduce inflammation and tissue destruction in these two diseases without the need for long-term immunosuppression or joint replacements, say the scientists.
The research was supported by Wellcome Trust, Versus Arthritis, and NIHR Birmingham Biomedical Research Centre, which is based at BHP founder-members University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham.
The research is part of the Arthritis Therapy Acceleration Programme (A-TAP), a joint alliance between the Universities of Birmingham and Oxford, which aims to ensure that world-class basic science observations are accelerated into early-phase experimental therapy for patients.
“If we compare fibroblasts to soil, this research has shown for the first time that not all soil is the same.
“Just as there are different layers of soil in our gardens – top soil and subsoil – there are different types of fibroblasts in our joints – and each layer seems to be associated with a different type of arthritis.
“From a research perspective this is exciting, but the clinical implications are also very important too. For the first time, we have identified two different types of fibroblasts in the joint, which, just like the different types of soil, lead to different types of arthritis.
“The top soil is what goes wrong in osteoarthritis, whereas in rheumatoid arthritis it’s the subsoil that is at fault.
“When patients are seen in clinic and we can’t help them, it motivates us to think creatively about how we conduct our research and classify disease.
“We have now discovered a new way to classify, and therefore treat, arthritis based on the underlying cell, rather than just the clinical features and genes involved.
“Current therapies work like weed killer – they kill the weeds but the weeds come back if you don’t continue to apply the weed killer. Our research will facilitate research aimed at changing the top soil, subsoil – or both – to treat arthritis.
“To know we are getting closer to offering patients new solutions is very exciting and we are doing it because we are finally looking at diseases using a process-driven cell based approach through the A-TAP project.”
Chief investigator Professor Chris Buckley, of the University of Birmingham’s Institute of Inflammation and Ageing and Director of Clinical Research at the Kennedy Institute at the University of Oxford
Two recent technical and clinical advances have helped lead to the researchers’ discovery: minimally invasive biopsies and single-cell sequencing. These two developments have allowed the research team to investigate fibroblast cells and their location in the joint as never before, ultimately identifying and describing the biology of distinct subsets of fibroblasts responsible for mediating either inflammation or cartilage/bone damage in arthritis.
“Rheumatoid arthritis is challenging to treat. It causes chronic inflammation in joints, leading to pain, swelling and, over time, damage to the joint. This is due to the body’s own immune system attacking the joints, which leads to an influx of immune cells in the lining of the joint.
“Current treatments target these immune cells either directly or by trying to disrupt the signals that attract the cells to the joint. No treatments directly target fibroblasts, key effector cells in the pathology of this disease.
“Thanks to advances in technology we have now, for the first time, been able to identify which fibroblasts are pathogenic in arthritis and how they contribute to disease.
Importantly, we found that by getting rid of these fibroblasts from the joint we could reduce the influx of immune cells to the joint, leading to less inflammation and destruction.
“These findings mean we now have a clear rationale for developing drugs that can target joint fibroblasts directly and provide more effective treatment for persistent disease.”
First author Dr Adam Croft, currently NIHR Academic Clinical Lecturer in Rheumatology at the University of Birmingham and previously funded by a Wellcome Trust Clinical Career Development Fellowship